← Back to patent-cliff list
CAS 200936-59-0
tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)-5-oxopentanoate
Codes: Foxy-5-003
Application context (from source-drug indications)
Colon cancerFoxy-5Prostate cancerFoxy-5Metastatic breast cancerFoxy-5Colorectal cancerFoxy-5
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Foxy-5 | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid→tert-butyl L-leucinate hydrochloride→tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)-5-oxopentanoate→tert-butyl (5R,8S,11S)-8-(3-(tert-butoxy)-3-oxopropyl)-1-(9H-fluoren-9-yl)-11-isobutyl-3,6,9-trioxo-5-((tritylthio)methyl)-2-oxa-4,7,10-triazadodecan-12-oate→tert-butyl (8R,11S,14S)-11-(3-(tert-butoxy)-3-oxopropyl)-1-(9H-fluoren-9-yl)-14-isobutyl-3,6,9,12-tetraoxo-8-((tritylthio)methyl)-2-oxa-4,7,10,13-tetraazapentadecan-15-oate→di-tert-butyl (2S,5S,8R,14S)-14-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(3-(tert-butoxy)-3-oxopropyl)-2-isobutyl-4,7,10,13-tetraoxo-8-((tritylthio)methyl)-3,6,9,12-tetraazahexadecanedioate→di-tert-butyl (2S,5S,8R,14S)-14-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methylthio)butanamido)-5-(3-(tert-butoxy)-3-oxopropyl)-2-isobutyl-4,7,10,13-tetraoxo-8-((tritylthio)methyl)-3,6,9,12-tetraazahexadecanedioate→di-tert-butyl (2S,5S,8R,14S)-5-(3-(tert-butoxy)-3-oxopropyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-4,7,10,13-tetraoxo-8-((tritylthio)methyl)-3,6,9,12-tetraazahexadecanedioate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.